Alnylam Pharmaceuticals, Inc. number of employees

Alnylam Pharmaceuticals, Inc. reported 2,500 employees at December 31, 2025 in its latest annual report, up 270 (12.1%) on the year before. That compares with 1,665 at December 31, 2021. Revenue per employee was $1.5m.

Headcount by year

Fiscal year end	Employees	Change	Revenue per employee	Source
December 31, 2025	2,500	+270 (12.1%)	$1.5m	10-K, filed February 12, 2026
December 31, 2024	2,230	+130 (6.2%)	$1.0m	10-K, filed February 13, 2025
December 31, 2023	2,100	+98 (4.9%)	$870,615	10-K, filed February 15, 2024
December 31, 2022	2,002	+337 (20.2%)	$518,191	10-K, filed February 23, 2023
December 31, 2021	1,665	—	$507,079	10-K, filed February 10, 2022

What the annual reports say

Human Capital Management As of December 31, 2025, we employed approximately 2,500 full-time employees, of whom approximately 1,945 were employed in the U.S. and approximately 555 were employed outside of the U.S. 2025 annual report
Human Capital Management As of December 31, 2024, we employed approximately 2,230 full-time employees, of whom approximately 1,760 were employed in the U.S. and approximately 470 were employed outside of the U.S. 2024 annual report
Human Capital Management As of December 31, 2023, we employed approximately 2,100 full-time employees, of whom approximately 1,650 were employed in the U.S. and approximately 450 were employed outside of the U.S. 2023 annual report
Human Capital Management As of December 31, 2022, we employed 2,002 full-time employees, of whom approximately 1,570 were employed in the U.S. and approximately 432 were employed outside of the U.S. 2022 annual report
Human Capital Management As of December 31, 2021, we employed 1,665 full-time employees, of whom approximately 1,290 were employed in the U.S. and approximately 375 were employed outside of the U.S. 2021 annual report

Headcount as the company states it in Item 1 of its annual report (some count full-time equivalents or exclude part-time and temporary staff), at the date it gives. Years where the report states no clear total are left out rather than estimated. Changes can reflect acquisitions and disposals as well as hiring and job cuts.

Compare with peers

Head to head: ALNY vs NBIX ALNY vs BMRN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Alnylam Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Alnylam Pharmaceuticals, Inc.